Table 3.

Electron microscopy findings before and after eculizumab treatment

Deposits (S/G, 0–3+)	DDD1		DDD3		C3GN1		C3GN2		C3GN3
	Before	After	Before	After	Before	After	Before	After	Before	After
Mesangial	G 3+	G 2+	G 2+	S 1+	G 2+	G 2+	G 3+	G 3+a	G 2+	G 2+
Subendothelial	0	0	0	0	S 2+	G 3+a	G 3+	G 3+a	S 1+	S 1+
Subepithelial	0	0	0	0	S 1+	0	0	0	S 1+	S 1+
Intramembranous	G 3+	G 2+	S 1+	S 1+	S 2+	S 1+	0	S 1+a	S 1+	S 1+
TBM	S 2+	S 3+	S 2+	S 2+	S 1+	S 1+	S 2+	S 2+	S 1+	S 2+
Bowman's capsule	S 2+	S 2+	S 1+	S 1+	0	0	0	0	0	0
Vessel wall	0	0	0	0	0	S 1+a	0	0	0	0
Podocyte effacement (%)	80	50	20	30	80	80	20	75	20	10
Glomeruli (n)	4	5	3	3	6	4	3	4	5	6

S, segmental; G, global.

^aSome of these deposits had a distinctly punctate, finely granular appearance, different from the deposits seen in the pretreatment biopsies. These granular deposits may represent deposition of the mAb, eculizumab.